Abiomed Inc
ABMD
ABMD was delisted on the 21st of December, 2022.
500 hedge funds and large institutions have $13.8B invested in Abiomed Inc in 2022 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 173 increasing their positions, 182 reducing their positions, and 51 closing their positions.
47% more call options, than puts
Call options by funds: $49.4M | Put options by funds: $33.7M
18% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 51
1% more funds holding
Funds holding: 496 → 500 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 182
8% less capital invested
Capital invested by funds: $15.1B → $13.8B (-$1.22B)
Top Buyers
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$170M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$166M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$65M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$51.5M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$40.2M |
ABMD Hedge Fund Activity: Q1 2022 in Review
500 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q1 2022, worth a combined $13.8B — down 8.1% from $15.1B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new ABMD positions and 51 closed out — a net gain of 9 holders — while 173 added to existing stakes and 182 trimmed.
The largest buyer was Generation Investment Management, opening a new position worth an estimated $404M. The largest seller was Wellington Management Group, cutting an estimated $170M.
- 500 institutional investors held Abiomed Inc (ABMD) as of Q1 2022, up from 496 in Q4 2021.
- Funds reported $13.8B of Abiomed Inc stock for Q1 2022, down 8.1% quarter-over-quarter.
- 60 funds opened new Abiomed Inc positions in Q1 2022 and 51 closed out, a net change of +9 holders.
- The largest Abiomed Inc buyer in Q1 2022 was Generation Investment Management, an estimated $404M added.
- The largest Abiomed Inc seller in Q1 2022 was Wellington Management Group, an estimated $170M sold.
Based on aggregated 13F filings for Q1 2022.